BONE REGULATORY MECHANISMS DESTRUCTION IN EXPERIMENTAL CHRONIC KIDNEY DISEASE.

Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994) Pub Date : 2016-01-01 DOI:10.15407/fz62.03.054

S B Pavlov, M V Kumechko, O B Litvinova, N M Babenko, A V Goncharova

{"title":"BONE REGULATORY MECHANISMS DESTRUCTION IN EXPERIMENTAL CHRONIC KIDNEY DISEASE.","authors":"S B Pavlov, M V Kumechko, O B Litvinova, N M Babenko, A V Goncharova","doi":"10.15407/fz62.03.054","DOIUrl":null,"url":null,"abstract":"<p><p>The aim of our study was to investigate the role of intercellular\nmediators – interleukin-1 receptor antagonist (IL-1 RA),\ninterleukin-17 (IL-17), receptor activator of nuclear factor kB\nligand (RANKL) and osteoprotegerin in the mechanisms of\nmetabolic regulation of renal and bone tissue on model of violations\nof bone remodeling in chronic kidney disease (CKD).\nIt was found a significant increase in the content of cytokines\nIL-1 RA (4,207 ± 0,546 pg/ml), IL-17 (33,944 ± 0,938 pg/\nml), osteoprotegerin (28,338 ± 1,223 pg/ml) and RANKL\n(0,184 ± 0,018 pmol/l) in the serum of animals in violation\nof bone remodeling in CKD compared with the contents of\nthe studied cytokines in animals in the control group (2,529\n± 0,132 pg/ml, 28,166 ± 0,526 pg/ml, 21,588 ± 0,763 pg/ml\nand 0,131 ± 0,006 pmol/l, respectively) (P<0.05). The obtained\ncorrelations reflect the relationship between regulation of bone\nremodeling and the development of inflammation in CKD.\nThe imbalance between pro- and anti-inflammatory cytokine\nplays an important role both in the development of CKD and\nin processes of bone remodeling.</p>","PeriodicalId":73031,"journal":{"name":"Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994)","volume":"62 3","pages":"54-9"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15407/fz62.03.054","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 7

Abstract

The aim of our study was to investigate the role of intercellular mediators – interleukin-1 receptor antagonist (IL-1 RA), interleukin-17 (IL-17), receptor activator of nuclear factor kB ligand (RANKL) and osteoprotegerin in the mechanisms of metabolic regulation of renal and bone tissue on model of violations of bone remodeling in chronic kidney disease (CKD). It was found a significant increase in the content of cytokines IL-1 RA (4,207 ± 0,546 pg/ml), IL-17 (33,944 ± 0,938 pg/ ml), osteoprotegerin (28,338 ± 1,223 pg/ml) and RANKL (0,184 ± 0,018 pmol/l) in the serum of animals in violation of bone remodeling in CKD compared with the contents of the studied cytokines in animals in the control group (2,529 ± 0,132 pg/ml, 28,166 ± 0,526 pg/ml, 21,588 ± 0,763 pg/ml and 0,131 ± 0,006 pmol/l, respectively) (P<0.05). The obtained correlations reflect the relationship between regulation of bone remodeling and the development of inflammation in CKD. The imbalance between pro- and anti-inflammatory cytokine plays an important role both in the development of CKD and in processes of bone remodeling.

查看原文本刊更多论文

实验性慢性肾脏疾病的骨调节机制破坏。

本研究旨在探讨白细胞介素-1受体拮抗剂(IL-1 RA)、白细胞介素-17 (IL-17)、核因子kBligand受体激活剂(RANKL)和骨保护素等细胞间介质在慢性肾病(CKD)骨重塑破坏模型中肾脏和骨组织代谢调节机制中的作用。结果发现，CKD骨重塑动物血清中细胞因子il -1 RA(4,207±0,546 pg/ml)、IL-17(33,944±0,938 pg/ml)、骨保护素(28,338±1,223 pg/ml)和RANKL(0,184±0,018 pmol/l)的含量明显高于对照组(分别为2,529±0,132 pg/ml、28,166±0,526 pg/ml、21,588±0,763 pg/ml和0,131±0,006 pmol/l)

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994)

CiteScore

0.60

自引率

0.00%

发文量